Demichelis-Gómez Roberta, Pérez-Sámano Daniela, Bourlon Christianne
Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.
Curr Oncol Rep. 2019 Feb 4;21(2):17. doi: 10.1007/s11912-019-0759-5.
The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.
Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Currently, the only bispecific antibody (bsAb) approved for its use in hematologic malignancies is blinatumomab. However, multiple trials are under development not only to explore blinatumomab's clinical activity in other neoplasia, such as lymphoma or multiple myeloma, but also to develop new molecules against different antigens.
本综述旨在讨论目前关于双特异性抗体（bsAb）在血液系统恶性肿瘤中应用的建议，并探索该领域的未来发展。
双特异性抗体是能够靶向两个不同抗原结合位点的分子：一个针对肿瘤抗原，另一个用于激活细胞毒性细胞。针对急性淋巴细胞白血病（ALL）的双特异性抗体blinatumomab进行的II/III期试验已证明其在治疗成人和儿童微小残留病（MRD+）以及复发难治性（r/r）费城染色体阳性（Ph+）和阴性（Ph-）ALL方面的疗效。目前，唯一被批准用于血液系统恶性肿瘤的双特异性抗体（bsAb）是blinatumomab。然而，多项试验正在进行中，不仅是为了探索blinatumomab在其他肿瘤（如淋巴瘤或多发性骨髓瘤）中的临床活性，也是为了开发针对不同抗原的新分子。
